tiprankstipranks
Alnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini
PremiumCompany AnnouncementsAlnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini
2M ago
Alnylam Pharmaceuticals’ New Regulation Risk – A Cause for Worry?
PremiumMarket News
Alnylam Pharmaceuticals’ New Regulation Risk – A Cause for Worry?
2M ago
Alnylam price target lowered to $161 from $171 at Wells Fargo
PremiumThe Fly
Alnylam price target lowered to $161 from $171 at Wells Fargo
2M ago
Alnylam post-earnings selloff overdone, says Citi
PremiumThe FlyAlnylam post-earnings selloff overdone, says Citi
2M ago
Alnylam downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Alnylam downgraded to Neutral from Buy at Goldman Sachs
2M ago
Alnylam reports Q4 EPS (77c), consensus ($1.32)
PremiumThe Fly
Alnylam reports Q4 EPS (77c), consensus ($1.32)
2M ago
Chardan lays out top 4 biotech picks for 2024
PremiumThe FlyChardan lays out top 4 biotech picks for 2024
3M ago
Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
3M ago
PepGen appoints DeLena as General Counsel, Secretary
PremiumThe Fly
PepGen appoints DeLena as General Counsel, Secretary
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100